Browse by author
Lookup NU author(s): Professor Brian Walker
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Congenital adrenal hyperplasia (CAH) is a genetic disorder caused by defective steroidogenesis that results in glucocorticoid deficiency; the most common underlying mutation is in the gene that encodes 21-hydroxylase. Life-saving glucocorticoid treatment was introduced in the 1950s, and the number of adult patients is now growing; however, no consensus has been reached on the management of CAH beyond childhood. Adult patients are prescribed a variety of glucocorticoids, including hydrocortisone, prednisone, prednisolone, dexamethasone and combinations of these drugs taken in either a circadian or reverse circadian regimen. Despite these personalized treatments, biochemical control of CAH is only achieved in approximately one-third of patients. Some patients have a poor health status, with an increased incidence of obesity and osteoporosis, and impaired fertility and quality of life. The majority of poor health outcomes seem to relate to inadequate treatment rather than the genotype of the patient. Patients receiving high doses of glucocorticoids and the more potent synthetic long-acting glucocorticoids are at an increased risk of obesity, insulin resistance and a reduced quality of life. Further research is required to optimize the treatment of adult patients with CAH and improve health outcomes.
Author(s): Han TS, Walker BR, Arlt W, Ross RJ
Publication type: Review
Publication status: Published
Journal: Nature Reviews Endocrinology
Print publication date: 01/02/2014
Online publication date: 17/12/2013
Acceptance date: 01/01/1900
ISSN (print): 1759-5029
ISSN (electronic): 1759-5037
PubMed id: 24342885